DK3044214T3 - Peptidylnitrilforbindelser som dipeptidylpeptidase-I-inhibitorer - Google Patents
Peptidylnitrilforbindelser som dipeptidylpeptidase-I-inhibitorerInfo
- Publication number
- DK3044214T3 DK3044214T3 DK14761986.0T DK14761986T DK3044214T3 DK 3044214 T3 DK3044214 T3 DK 3044214T3 DK 14761986 T DK14761986 T DK 14761986T DK 3044214 T3 DK3044214 T3 DK 3044214T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitors
- dipeptidyl peptidase
- nitrile compounds
- peptidyl nitrile
- peptidyl
- Prior art date
Links
- 102000003902 Cathepsin C Human genes 0.000 title 1
- 108090000267 Cathepsin C Proteins 0.000 title 1
- -1 Peptidyl nitrile compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13183519 | 2013-09-09 | ||
| EP14151979 | 2014-01-21 | ||
| PCT/EP2014/069088 WO2015032945A1 (en) | 2013-09-09 | 2014-09-08 | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3044214T3 true DK3044214T3 (da) | 2017-11-13 |
Family
ID=51535425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14761986.0T DK3044214T3 (da) | 2013-09-09 | 2014-09-08 | Peptidylnitrilforbindelser som dipeptidylpeptidase-I-inhibitorer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9856228B2 (enExample) |
| EP (1) | EP3044214B1 (enExample) |
| JP (1) | JP6408008B2 (enExample) |
| CN (1) | CN105612149A (enExample) |
| AU (1) | AU2014317048B2 (enExample) |
| CA (1) | CA2923484C (enExample) |
| DK (1) | DK3044214T3 (enExample) |
| EA (1) | EA029030B1 (enExample) |
| SG (1) | SG11201601150WA (enExample) |
| WO (2) | WO2015032943A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105612149A (zh) | 2013-09-09 | 2016-05-25 | 普罗技迈克斯公司 | 作为二肽基肽酶i抑制剂的肽基腈化合物 |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| DK3265452T3 (en) * | 2015-03-05 | 2020-06-08 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| ES2912276T3 (es) * | 2015-04-07 | 2022-05-25 | Ela Pharma Ltd | Composiciones para tratar y/o prevenir necrosis celular o tisular que seleccionan como diana específicamente catepsina C y/o CELA1 y/o CELA3A y/o enzimas estructuralmente relacionadas con las mismas |
| PT3758708T (pt) | 2018-03-01 | 2025-02-13 | Astrazeneca Ab | Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| AU2021314104A1 (en) | 2020-07-20 | 2023-01-19 | Insmed, Inc. | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| CN114159446A (zh) | 2020-09-11 | 2022-03-11 | 中国科学院上海营养与健康研究所 | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 |
| WO2023243601A1 (ja) | 2022-06-13 | 2023-12-21 | モジュラス株式会社 | アザシクロアルキルカルボニル環状アミン化合物 |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性ｄｐｐ１阻害剤及びその用途 |
| WO2025162472A1 (en) | 2024-01-31 | 2025-08-07 | Insmed Incorporated | Linear dipeptidyl peptidase 1 inhibitors and uses thereof |
| WO2026148258A2 (en) | 2025-01-03 | 2026-07-09 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902181B2 (en) * | 2007-12-12 | 2011-03-08 | Astrazeneca Ab | Compounds 010 |
| KR100903499B1 (ko) | 2007-12-27 | 2009-06-18 | 엔에이치엔비즈니스플랫폼 주식회사 | 검색 의도 분류에 따른 광고 제공 방법 및 상기 방법을수행하기 위한 시스템 |
| EA201190235A1 (ru) * | 2009-05-07 | 2012-05-30 | Астразенека Аб | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 |
| WO2010142985A1 (en) * | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
| WO2012119941A1 (en) * | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| WO2012130299A1 (en) | 2011-03-30 | 2012-10-04 | Prozymex A/S | Peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| CN105612149A (zh) | 2013-09-09 | 2016-05-25 | 普罗技迈克斯公司 | 作为二肽基肽酶i抑制剂的肽基腈化合物 |
-
2014
- 2014-09-08 CN CN201480049595.8A patent/CN105612149A/zh active Pending
- 2014-09-08 EA EA201690561A patent/EA029030B1/ru not_active IP Right Cessation
- 2014-09-08 WO PCT/EP2014/069081 patent/WO2015032943A1/en not_active Ceased
- 2014-09-08 US US14/917,147 patent/US9856228B2/en active Active
- 2014-09-08 EP EP14761986.0A patent/EP3044214B1/en active Active
- 2014-09-08 SG SG11201601150WA patent/SG11201601150WA/en unknown
- 2014-09-08 WO PCT/EP2014/069088 patent/WO2015032945A1/en not_active Ceased
- 2014-09-08 AU AU2014317048A patent/AU2014317048B2/en active Active
- 2014-09-08 CA CA2923484A patent/CA2923484C/en active Active
- 2014-09-08 JP JP2016539571A patent/JP6408008B2/ja active Active
- 2014-09-08 DK DK14761986.0T patent/DK3044214T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3044214A1 (en) | 2016-07-20 |
| EA201690561A1 (ru) | 2016-07-29 |
| AU2014317048B2 (en) | 2018-05-10 |
| NZ718128A (en) | 2021-04-30 |
| JP6408008B2 (ja) | 2018-10-17 |
| EA029030B1 (ru) | 2018-01-31 |
| WO2015032943A1 (en) | 2015-03-12 |
| CN105612149A (zh) | 2016-05-25 |
| CA2923484A1 (en) | 2015-03-12 |
| JP2016529306A (ja) | 2016-09-23 |
| SG11201601150WA (en) | 2016-03-30 |
| AU2014317048A1 (en) | 2016-04-07 |
| US20160207900A1 (en) | 2016-07-21 |
| EP3044214B1 (en) | 2017-08-09 |
| WO2015032945A1 (en) | 2015-03-12 |
| CA2923484C (en) | 2022-09-06 |
| US9856228B2 (en) | 2018-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3080100T (lt) | Lizinui specifinės demetilazės-1 inhibitoriai | |
| DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
| HUE036259T2 (hu) | Inhibitor vegyületek | |
| DK3436461T3 (da) | Pyrrolotriazinforbindelser som tam-inhibitorer | |
| DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
| DK3181567T3 (da) | Pyrazolopyrimidinforbindelser som kinasehæmmere | |
| DK3342771T3 (da) | Heterocykliske amider som kinaseinhibitorer | |
| LT2920168T (lt) | Heterociklinis gliutaminazės inhibitorius | |
| LT3057586T (lt) | Bromodomeno inhibitoriai | |
| LT2841428T (lt) | Dnr-pk inhibitoriai | |
| HUE049345T2 (hu) | Nyújtott hatóanyag-leadású dózisformák JAK1 inhibitorhoz | |
| EP2969007A4 (en) | HISTONE DEMETHYLASE INHIBITORS | |
| DK3277677T3 (da) | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere | |
| IL227594A0 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| SI3323814T1 (sl) | (2s) -n - ((ls) -1-ciano-2-feniletil) -1,4-oksazepan-2-karboksamidi kot inhibitorji dipeptidil peptidaze i | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| DK4275756T3 (da) | Bipyrazol-derivater som jak-hæmmere | |
| DK2981526T3 (da) | Naphthylureaderivater til anvendelse som kinaseinhibitorer | |
| SI3105226T1 (sl) | Ciklopropilamini kot zaviralci LSD1 | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| CO7071137A2 (es) | Compuetos inhibidores de beta-lactamasas | |
| AR095266A1 (es) | Inhibidores de bromodominios tetraciclicos | |
| HUE042393T2 (hu) | Multiszubsztituált aromás vegyületek, mint szerinproteáz inhibitorok | |
| HRP20181786T1 (hr) | Inhibitori aktivacije t-stanica | |
| DK2678329T3 (da) | Triazolopyridinforbindelser som pim-kinase-hæmmere |